Skip to content

Supraclavicular Brachial Plexus Block as Opioid Sparing Technique in Pediatrics Undergoing Arteriovenous Fistula Creation

Supraclavicular Brachial Plexus Block as Opioid Sparing Technique in Pediatrics Undergoing Arteriovenous Fistula Creation: A Randomized Controlled Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07012616
Enrollment
50
Registered
2025-06-10
Start date
2025-06-10
Completion date
2026-01-15
Last updated
2026-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arteriovenous Fistula, Opioid Sparing, Pediatric, Supraclavicular Brachial Plexus Block

Brief summary

This study aims to evaluate the efficacy of supraclavicular brachial plexus block as an opioid-sparing technique in pediatric patients undergoing arteriovenous fistula creation.

Detailed description

The global incidence of end-stage renal failure (ESRF) is increasing. The preferred procedure for patients with ESRF undergoing maintenance Haemodialysis (HD) is the placement of an arteriovenous fistula (AVF). In patients with ESRF, brachial plexus block (BPB) is frequently employed to administer anesthesia for the establishment or modification of AVF. This technique offers pain relief, sympathetic blockade, ideal surgical conditions, and a sufficient duration of postoperative block, preventing arterial spasms and graft thrombosis

Interventions

OTHERSupraclavicular brachial plexus block

Patients will receive an ultrasound-guided supraclavicular brachial plexus block.

Sponsors

Tanta University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
6 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Age from 6 to 18 years. * Both sexes. * American Society of Anesthesiology (ASA) physical status I- III. * Undergoing arteriovenous fistula creation under general anesthesia.

Exclusion criteria

* Allergy to local anesthetics. * Infection at the site of block. * Local infection. * Coagulation disorder. * Previously failed or revision of blocked arteriovenous fistula.

Design outcomes

Primary

MeasureTime frame
Intraoperative fentanyl consumptionIntraoperatively

Secondary

MeasureTime frameDescription
Total opioid consumption24 hours postoperativelyRescue analgesia of 0.5 µg/kg fentanyl will be given if the Wong-Baker score is 4 more.
Time to the 1st rescue analgesia24 hours postoperativelyTime to the first request for the rescue analgesia (time from end of surgery to the first dose of fentanyl administrated) will be assessed.
Degree of pain24 hours postoperativelyDegree of pain will be assessed using Wong-Baker score (0 to 10), 0= no hurt and 10= hurts worst. Wong-Baker score will be assessed at post-anesthesia care unit (PACU), 4, 6, 8, 12, 18 and 24 h postoperatively.
Patient satisfaction24 hours postoperativelyDegree of patient satisfaction will be assessed on a 5-point Likert scale patient satisfaction (1, extremely dissatisfied; 2, unsatisfied; 3, neutral; 4, satisfied; 5, extremely satisfied).
Incidence of adverse events24 hours postoperativelyIncidence of adverse events such as local anesthetic systemic toxicity (LAST), bradycardia, hypotension, PONV, respiratory depression, or any other complication will be recorded.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026